Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.
American Association of Individual Investors7h
3 Undervalued Biotechnology Stocks for Thursday, March 27
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Why this trade expert says the U.S. economy will stall next quarter - and Apple's investment claims are inflated
Setser dismissed Apple Inc.'s (AAPL) claim that it will invest $500 billion in the U.S. over the next four years. "Apple is taking credit for making orders for TSMC's future chip production in the U.S ...
Opinion
Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.
For greater potential upside, consider earlier-stage smid-cap biotech names. Small- and midcap biotech stocks are riskier, but have been hardest hit in the sector's decline. "Smid-cap biotech looks ...
Why Pfizer Is My Largest Healthcare Position
Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't ...
WSJ report of probe to have limited impact on Pfizer, says Citi
Citi analyst Geoff Meacham keeps a Neutral rating on Pfizer (PFE) with a $27 price target after the Wall Street Journal reported that U.S.
Pfizer Stock Slips After Report on Vaccine Timing Probe
Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...
Retail Stocks To Add to Your Watchlist – March 23rd
Tesla, Apple, Microsoft, Amazon.com, and Pfizer are the five Retail stocks to watch today, according to MarketBeat’s stock ...
24/7 Wall St.3d
Why Schwab's High-Yield Dividend ETF (SCHD) Is the Safest Way to Stay Invested Today
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
Pfizer: Bulls Need To Check Out Its Graham P/E
Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025
If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The ...
Stockhouse7d
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...